In conclusion, by engineering an oncolytic virus that concurrently (1) amplifies tumor neoantigens, (2) recruits cDC1 antigen-presenting cells, and (3) generates T-cell memory, NeoViron has established a new paradigm for overcoming immunotherapy resistance in low-TMB tumors. This evidence concerns the gene MPPE1 and neoplasm.